Millipore Sigma Vibrant Logo

189299 ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem

The ATR/CDK Inhibitor, NU6027, also referenced under CAS 220036-08-8, controls the biological activity of ATR/CDK. This small molecule/inhibitor is primarily used for Cancer applications.

ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: ATR Inhibitor, NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, CDK2 Inhibitor, NU6027

View This Product on Sigma-Aldrich
189299
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
220036-08-8C₁₁H₁₇N₅O₂

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
189299-10MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 ｶﾞﾗｽﾋﾞﾝ 10 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable, pyrimidine derivative that acts as an ATP-competitive CDK Inhibitor (Ki = 2.5 µM for CDK1, and Ki = 1.3 µM for CDK2), and demonstrates cytostatic properties among a panel of 57 cancer cell lines. Also inhibits ATR kinase (IC50 = 6.7 µM in MCF7 cells), but does not interfere with irradiation-induced autophosphorylation of DNA-PK or ATM. Potentiates a range of DNA-damaging cytotoxic drugs such as hydroxyurea (1.8-fold) and cisplatin (1.4-fold) at 10 µM, but not the anti-mitotic paclitaxel. Attenuates G2/M arrest following DNA damage and inhibits RAD51 focus formation. Shown to be synthetically lethal when DNA single-strand break repair is impaired in PARP-inhibited cells.
      Catalogue Number189299
      Brand Family Calbiochem®
      SynonymsATR Inhibitor, NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, CDK2 Inhibitor, NU6027
      References
      ReferencesPeasland, A., et al. 2011., Br J Cancer. 105, 372.
      Arris, C.E, et al. 2000., J Med Chem. 43, 2797.
      Product Information
      CAS number220036-08-8
      FormReddish-purple powder
      Hill FormulaC₁₁H₁₇N₅O₂
      Chemical formulaC₁₁H₁₇N₅O₂
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      189299-10MGCN 04055977221718

      Documentation

      ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      189299

      参考資料

      参考資料の概要
      Peasland, A., et al. 2011., Br J Cancer. 105, 372.
      Arris, C.E, et al. 2000., J Med Chem. 43, 2797.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-May-2012 JSW
      SynonymsATR Inhibitor, NU6027, 2,6-diamino-4-cyclohexyl-methyloxy-5-nitroso-pyrimidine, CDK2 Inhibitor, NU6027
      DescriptionA cell-permeable, pyrimidine derivative that acts as an ATP-competitive CDK Inhibitor (Ki = 2.5 µM for CDK1, and Ki = 1.3 µM for CDK2), and demonstrates cytostatic properties among a panel of 57 cancer cell lines. Also inhibits ATR kinase (IC50 = 6.7 µM in MCF7 cells), but does not interfere with irradiation-induced autophosphorylation of DNA-PK or ATM. Potentiates a range of DNA-damaging cytotoxic drugs such as hydroxyurea (1.8-fold) and cisplatin (1.4-fold) at 10 µM, but not the anti-mitotic paclitaxel. Attenuates G2/M arrest following DNA damage and inhibits RAD51 focus formation. Shown to be synthetically lethal when DNA single-strand break repair is impaired in PARP-inhibited cells.
      FormReddish-purple powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number220036-08-8
      Chemical formulaC₁₁H₁₇N₅O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (10 mg/ml; clear, blue solution)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesPeasland, A., et al. 2011., Br J Cancer. 105, 372.
      Arris, C.E, et al. 2000., J Med Chem. 43, 2797.